The impact of memantine and cholinesterase inhibitor initiation for alzheimer disease on the use of antipsychotic agents: Analysis using the Régie de l'assurance maladie du Québec database

Canadian Journal of Psychiatry

Volumn 58, Issue 4, 2013, Pages 195-200

  Lachaine, Jean ^a   Beauchemin, Catherine ^a   Crochard, Anne ^b   Bineau, Sébastien ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Lundbeck   (France)

Author keywords

Alzheimer; Antipsychotics; Cholinesterase inhibitor; Memantine

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE;

ALZHEIMER DISEASE; ARTICLE; CANADA; COHORT ANALYSIS; HUMAN; OUTCOME ASSESSMENT; PRESCRIPTION; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS;

EID: 84878284140     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371305800404     Document Type: Article

References (24)

1. Alzheimer Society of Canada. Rising tide: the impact of dementia on Canadian society - executive summary [Internet]. Toronto (ON): Alzheimer Society of Canada; 2010 [cited 2011 Feb 8]. Available from: http://alzheimersociety. sitesystems.ca/sitecore/shell/Controls/ Rich Text Editor/~/media/Files/national/ pdfs/English/Advocacy/ ASC-Rising Tide-Executive Summary-Eng.ashx.
2. Statistic Canada. Les principales causes de décès [Internet]. Ottawa (ON): Statistic Canada; 2011 [cited 2011 Feb 8]. Available from: http://www.statcan.gc.ca/daily-quotidien/111101/dq111101b-fra.htm.
3. Labelle C. Alzheimer's disease [Internet]. Ottawa (ON): Library of Parliament; 2007 [cited 2011 Feb 8]. Available from: http://publications.gc.ca/ collections/collection-2008/lop-bdp/prb/ prb0239-1e.pdf.
4. Massoud F, Leger GC. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10): 579-588.
5. Ballard C, Day S, Sharp S, et al. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int Rev Psychiatry. 2008;20(4): 396-404.
6. Covinsky KE, Newcomer R, Fox P, et al. Patient and caregiver characteristics associated with depression in caregivers of patients with dementia. J Gen Intern Med. 2003;18(12): 1006-1014.
7. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162(11): 2022-2030.
8. Boller F, Verny M, Hugonot-Diener L, et al. Clinical features and assessment of severe dementia. A review. Eur J Neurol. 2002;9(2): 125-136.
9. Hashimoto M. Pharmacologic therapies of BPSD: messages from psychiatrists. Rinsho Shinkeigaku. 2011;51(11): 857-860.
10. Senanarong V, Jamjumras P, Harmphadungkit K, et al. A counseling intervention for caregivers: effect on neuropsychiatric symptoms. Int J Geriatr Psychiatry. 2004;19(8): 781-788.
11. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA. 2005;294(15): 1934-1943.
12. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11): 775-786.
13. US Food and Drug Administration. FDA Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances [Internet]. Silver Spring (MD): US Food and Drug Administration; 2005 [cited 2011 Feb 8]. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ PublicHealthAdvisories/ ucm053171.htm.
14. Singh S, Wooltorton E. Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ. 2005;173(3):252.
15. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5): 537-545.
16. Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3): 341-348.
17. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr. 2009;21(5): 813-824.
18. Vidal JS, Lacombe JM, Dartigues JF, et al. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology. 2008;31(3): 193-200.
19. Régie de l'Assurance Maladie du Québec (RAMQ). Régie: mission et organisation - clientèles [Internet]. Montreal (QC): RAMQ; 2011 [cited 2011 Feb 15]. Available from: http://www.ramq.gouv.qc. ca/fr/ regie/missorg/clienteles.shtml.
20. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4): 299-309.
21. Ramsay CR, Matowe L, Grilli R, et al. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. Int J Technol Assess Health Care. 2003;19(4): 613-623.
22. Hartmann DP, Gottman JM, Jones RR, et al. Interrupted time-series analysis and its application to behavioral data. J Appl Behav Anal. 1980;13(4): 543-559.
23. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3): 317-324.
24. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6): 600-607.